25x-NBOMe is the general form of the NBOMe series of psychedelic phenethylamines. The series had nearly no history of human use before 2010 when some of the first compounds became available for purchase from online research chemical vendors.
While members of this series are often misrepresented as LSD, a fundamental difference between them is that 25x-NBOMe is only active when taken through a sublingual or insufflated route. This means that to get the full effects, 25x-NBOMe blotter paper must be lightly chewed on for 20+ minutes and never immediately swallowed.
25x-NBOMe blotters cause numbness of the tongue and have a distinct taste that is often described as "strongly bitter", "metallic", or "chemical like". This is unlike LSD blotters, which will not cause numbness of the tongue and may be tasteless or have a slight flavor depending on the amount of ink on the blotter and the composition of the blotter paper.
Although these differences can be helpful in identifying an unwanted compound on a blotter, it is recommended that more reliable methods of identification be used, such as the use of testing reagents like the Ehrlich reagent.
Insufflation of these substances are highly discouraged due to numerous reports of people suffering dangerous and often fatal overdoses that have surfaced over the years.
In a comparison of 25x-NBOMe and 2C-x chemicals, each 25x-NBOMe molecule is a serotonergic N-benzyl derivative of the corresponding 2C-x molecule. This change in structure results in an increase in potency. It differs from the related 2C-x structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. The addition of this BOMe group also causes most of the compounds to have relatively the same duration, regardless of how long the 2C-x counterpart lasts.
List of 25x-NBOMe compounds
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Tolerance and addiction potential
Members of the 25x-NBOMe series are not habit-forming and the desire to use them can actually decrease with use. They are thought to be most often self-regulating.
Tolerance to the effects of any member of the 25x-NBOMe series is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back to baseline (in the absence of further consumption). Members of the 25x-NBOMe series present cross-tolerance with all psychedelics, meaning that after the consumption of any member of the 25x-NBOMe series all psychedelics will have a reduced effect.
Due to the very high potency and seemingly unpredictable effects the margin between a normal and an overdose of NBOMe compounds is extremely small when compared to many other substances. The exact toxic dose is unclear since it seems to depend a lot on personal physiology, rather than predominantly dose. However, various anecdotal reports suggest that dangerous side effects begin to appear when exceeding 1000 μg and it possibly becoming lethal for the more sensitive people at roughly 2000 μg. Reports of other people surviving much higher doses, sometimes even without any major side effects have been documented as well.
There is also the uncertainty of dosage on blotter paper since it is rather difficult to lay such an exact dosage. Insufflating, vaporizing or drinking tinctures of this substance is highly discouraged because of this and has been tied to many documented deaths. One study found that 25I‐NBOMe and 25C‐NBOMe blotter papers contained 'hotspots' with higher quantities of the drug, implying an inherent risk of overdosing.
The overdose effects of NBOMes are typically a dangerously high heart rate, blood pressure, hyperthermia and significant vasoconstriction also accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia and often seizures. The risks in an overdose include anything from organ failure to cardiac arrest and death. There are also multiple reports of people lethally injuring themselves or falling to death. Benzodiazepines or antipsychotics can help with the psychological effects during an overdose although medical attention should always be called in even a possible overdose of 25I-NBOMe.
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. Due to the highly unpredictable nature of the NBOMe series, it is generally advised to avoid mixing them with other psychoactive substances.
- 2C-T-X - The 2C-T-X phenethylamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
- 5-MeO-xxt - The 5-MeO tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
- Amphetamines - Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
- Caffeine - Caffeine can bring out the natural stimulation from psychedelic drugs to make it uncomfortable. High doses can cause anxiety which is hard to handle while tripping.
- Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
- Cocaine - Cocaine and NBOMes both provide considerable stimulation. When combined they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
- Lithium - Lithium is commonly prescribed in the treatment of [https://en.wikipedia.org/wiki/Bipolar_disorder bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably.
- MXE - As an NMDA antagonist, MXE potentiates NBOMes which can be unpleasantly intense.
- Tramadol - Tramadol is well known to lower seizure threshold and NBOMes have also shown a tendency to cause severe seizures
Serotonin syndrome risk
- MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.
- Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
- SSRIs - Such as citalopram and sertraline
- SNRIs - Such as tramadol and venlafaxine
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Austria: The 25x-NBOMe family is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
- United States: In the US, some of the 25x-NBOMe chemicals are listed as Schedule I substances and others may be considered analogues under the Federal Analogue Act.
- United Kingdom: The majority of synthesised 25x-NBOMe substances are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause. Any compounds not covered by the clause are illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., & Kristensen, J. L. (2014). Synthesis and structure–activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243-249. https://doi.org/10.1021/cn400216u
- Heim, Ralf (2004). "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur". Freie Universität Berlin. Retrieved 27 June 2015.
- Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMC 3963123 Freely accessible. PMID 24397362. https://doi.org/10.1021/cn400216u
- Ettrup, A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–693. PMID 21174090. https://doi.org/10.1007/s00259-010-1686-8
- Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths
- Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths
- Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths
- Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). "Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers". Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603.
- Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentin, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (1 March 2019). "Clinical and Toxicological Profile of NBOMes: A Systematic Review". Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182.
- Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). "2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo". Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274.
- Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi: . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.
- United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted